PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES MELLITUS AND DIABETIC NEPHROPATHY

吡马地定治疗 II 型糖尿病和糖尿病肾病患者

• 批准号: 6275964
• 负责人: William Irving Sivitz
• 金额: $ 1.92万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275964
• 关键词: cardiovascular disorder; clinical research; crosslink; diabetes mellitus therapy; diabetic nephropathy; drug adverse effect; drug screening /evaluation; human morbidity; human mortality; human subject; hydrazines; kidney disorder chemotherapy; kidney function; noninsulin dependent diabetes mellitus

The goal of the study is to evaluate the safety and efficacy of pimagedine, a nucleophilic hydrazine derivative, in preserving renal function in patients with type II diabetes mellitus and overt diabetic nephropathy. Parameters assessed include protein crosslinking, all- cause mortality, and cardiovascular mortality and morbidity.

这项研究的目的是评估阿司匹林的安全性和有效性。 亲核联氨类药物吡马西定在肾脏保存中的作用 2型糖尿病和显性糖尿病患者的功能 肾病。评估的参数包括蛋白质交联，所有- 造成死亡率、心血管死亡率和发病率。